Form 4: Teva CEO Francis Secures 1.5M Future RSU Grant

Teva Pharmaceutical Industries Ltd.'s President and CEO, Richard D. Francis, reported the future acquisition of over 1.5 million Restricted Share Units, vesting in early 2026.

Summary

• Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd., reported the acquisition of 1,511,425 Restricted Share Units (RSUs).
• These RSUs were received upon the satisfaction of performance criteria from previously granted performance share units.
• The first tranche of 620,110 RSUs is subject to time-based vesting and will vest on February 15, 2026.
• The second tranche of 891,315 RSUs is also subject to time-based vesting and will vest on March 3, 2026.
• Each RSU represents a contingent right to receive one ordinary share or its cash equivalent at the option of the Human Resources and Compensation Committee.
• The transaction date for these acquisitions is listed as January 27, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting the CEO's continued alignment with shareholder interests through significant equity compensation tied to performance and future vesting.

Positives

• The CEO, Richard D. Francis, is set to receive a significant equity grant of 1,511,425 Restricted Share Units, aligning his interests with long-term shareholder value.
• The grant is a result of the satisfaction of performance criteria from previous performance share units, indicating successful achievement of prior goals.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports executive compensation.

Future Outlook

The filing indicates a future outlook for Richard D. Francis's equity compensation, with 620,110 Restricted Share Units scheduled to vest on February 15, 2026, and an additional 891,315 Restricted Share Units vesting on March 3, 2026. These vestings are contingent on time-based criteria following the satisfaction of prior performance goals.

Industry Context

StockSavvy.ai notes that the grant of Restricted Share Units (RSUs) to a CEO, particularly those tied to performance criteria and subsequent time-based vesting, is a standard practice in executive compensation across the pharmaceutical industry. This structure aims to align executive incentives with long-term company performance and shareholder interests, a common approach seen in peers like Pfizer or Johnson & Johnson.

Comparison to Industry Standards

• The structure of this RSU grant, combining performance-based achievement with time-based vesting, aligns with best practices in executive compensation observed at major pharmaceutical companies globally.
• Companies such as Novartis and AstraZeneca frequently utilize similar equity-based incentives to retain key executives and motivate sustained performance.
• The size of the grant, over 1.5 million units, is substantial and reflects the CEO's strategic importance to Teva, comparable to equity awards granted to top executives at similarly sized global pharmaceutical firms.

Stakeholder Impact

• Shareholders: The grant aligns the CEO's interests with long-term shareholder value, potentially fostering sustained performance.
• Employees: May signal stability in leadership and a commitment to performance-based incentives within the company.

Next Steps

• The 620,110 Restricted Share Units are scheduled to vest on February 15, 2026.
• The 891,315 Restricted Share Units are scheduled to vest on March 3, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event, specifically the grant of Restricted Share Units to the CEO following the satisfaction of performance criteria. While positive for executive alignment, it does not present new information that would fundamentally alter the investment thesis for Teva Pharmaceutical Industries. Investors should continue to hold based on broader company fundamentals and market conditions, as this filing alone does not warrant a change in position.

Keywords

Teva Pharmaceutical Industries, TEVA, Richard D. Francis, Restricted Share Units, RSU, Executive Compensation, SEC Form 4, Equity Grant, Performance Share Units, Vesting